Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and a wide range of signs and symptoms (Compston and Coles, 2008). MS affects 2.5 million people worldwide each year and is the most debilitating neurological disease in young adults (Fernandes de Abreu et al., 2009).

The estimated prevalence and incidence of MS vary greatly between countries, within countries, and by age and sex. The World Health Organization (WHO) reports that the median estimated global prevalence is 30 cases per 100,000 population and the estimated incidence is approximately 2.5 cases per 100,000 population. Globally, MS has an average age at onset of 30 years and occurs about twice as frequently in women as in men (WHO, 2008).

Below mentioned figure presents the prevalent cases of MS in the 10MM for 2013 and 2023.

This report provides an overview of the risk factors and comorbidities, and global and historical trends of MS in the 10 major markets (10MM) (the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India). It includes a 10-year epidemiological forecast of MS prevalent and incident cases segmented by sex and age (in five-year increments beginning at 20 years and ending at ≥85 years) in the 10MM. GlobalData epidemiologists used country-specific sources published by peer-reviewed journals to estimate the incidence and prevalence of MS in each of the 10MM. To provide a thorough description of the MS patient population in each country, GlobalData epidemiologists segmented MS incident and
Executive Summary

GlobalData epidemiologists forecast that the seven major markets (7MM) (the US, France, Germany, Italy, Spain, the UK, and Japan) will see an annual growth rate of 0.32% during the forecast period, whereas the five EU markets (5EU) (France, Germany, Italy, Spain, and the UK) will have an annual growth rate that is about half that of the total 7MM (AGR: 0.14%). Of the 5EU markets, Spain will have the highest annual growth rate of 1.05% and Italy will have the highest annual decrease of negative 0.33%.

The prevalence and incidence of MS vary greatly by age, sex, and geographical location. Regional differences in MS prevalence and incidence could be due to several factors including diagnostic criteria used, availability of medical technology, genetic and environmental risk factors, frequency of comorbidities, and population age and sex structure.
# Table of Contents

1 Table of Contents ....................................................................................................................... 4

1.1 List of Tables ...................................................................................................................... 6

1.2 List of Figures ..................................................................................................................... 6

2 Introduction ................................................................................................................................. 7

2.1 Catalyst............................................................................................................................... 7

2.2 Related Reports .................................................................................................................. 7

2.3 Upcoming Reports .............................................................................................................. 7

3 Epidemiology .............................................................................................................................. 8

3.1 Disease Background ........................................................................................................... 8

3.2 Risk Factors ....................................................................................................................... 9

3.2.1 Family members of MS patients have a 1%–5% risk of developing MS......................... 9

3.2.2 Women are twice as likely to develop MS, but men have a worse prognosis............... 9

3.2.3 Caucasians have a higher risk of MS than any other race/ethnicity ............................... 10

3.2.4 Protective effect of vitamin D on MS may relate to latitude and month of birth.......... 10

3.2.5 Timing of environmental exposures affects MS risk.................................................... 11

3.2.6 Exposure to smoking may increase MS risk and worsen prognosis.......................... 11

3.3 Comorbidities .................................................................................................................... 12

3.3.1 Autoimmune diseases may be comorbidities of MS..................................................... 12

3.3.2 Mental comorbidities are found in up to 60% of MS patients and may affect relapse rates ..................................................................................................................................... 12

3.4 Global Trends ................................................................................................................... 13

3.4.1 North America ............................................................................................................... 13

3.4.2 Europe .......................................................................................................................... 14

3.4.3 Asia ................................................................................................................................ 15

3.5 Forecast Methodology ....................................................................................................... 16

3.5.1 Sources Used................................................................................................................. 18
# Table of Contents

3.5.2 Sources Not Used ..................................................................................................................................... 24  
3.5.3 Forecast Assumptions and Methods ........................................................................................................ 24  
3.6 Epidemiological Forecast of Multiple Sclerosis (2013–2023) .................................................................... 34  
3.6.1 Total Prevalent Cases of Multiple Sclerosis ........................................................................................... 34  
3.6.2 Age-Specific Prevalent Cases of Multiple Sclerosis .................................................................................. 36  
3.6.3 Sex-Specific Prevalent Cases of Multiple Sclerosis .................................................................................. 38  
3.6.4 Total Incident Cases of Multiple Sclerosis ............................................................................................. 40  
3.6.5 Age-Specific Incident Cases of Multiple Sclerosis .................................................................................... 42  
3.6.6 Sex-Specific Incident Cases of Multiple Sclerosis .................................................................................... 44  
3.6.7 Multiple Sclerosis Subtypes ..................................................................................................................... 46  
3.7 Discussion ................................................................................................................................................... 48  
3.7.1 Epidemiological Forecast Insight .............................................................................................................. 48  
3.7.2 Limitations of the Analysis ........................................................................................................................ 49  
3.7.3 Strengths of the Analysis .......................................................................................................................... 49  
4 Appendix ....................................................................................................................................................... 50  
4.1 Bibliography .................................................................................................................................................. 50  
4.2 About the Authors ........................................................................................................................................ 57  
4.2.1 Epidemiologists ......................................................................................................................................... 57  
4.2.2 Reviewers .................................................................................................................................................. 57  
4.2.3 Global Director of Epidemiology ............................................................................................................ 58  
4.2.4 Global Head of Healthcare ...................................................................................................................... 58  
4.3 About GlobalData ........................................................................................................................................ 59  
4.4 About EpiCast ............................................................................................................................................... 59  
4.5 Disclaimer .................................................................................................................................................... 60
Table of Contents

1.1 List of Tables
Table 1: Sources of Prevalence and Incidence Data Used in the Epidemiology Forecast ....................... 17
Table 2: 10MM, Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2013–2023 35
Table 3: 10MM, Prevalent Cases of MS, By Age, Men and Women, N (Row %), 2013 ............................... 37
Table 4: 10MM, Prevalent Cases of MS, Ages ≥20 Years, By Sex, N (Row %), 2013 ............................... 39
Table 5: 10MM, Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2013–2023 ..41
Table 6: 10MM, Incident Cases of MS, By Age, Men and Women, N (Row %), 2013 ............................... 43
Table 7: 10MM, Incident Cases of MS, By Sex, N (Row %), 2013 ............................................................. 45

1.2 List of Figures
Figure 1: 10MM, Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2013–2023 36
Figure 2: 10MM, Prevalent Cases of MS, By Age, Men and Women, N, 2013 ............................................. 38
Figure 3: 10MM, Prevalent Cases of MS, Ages ≥20 Years, By Sex, N, 2013 .............................................. 40
Figure 4: 10MM, Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2013–2023 ..42
Figure 5: 10MM, Incident Cases of MS, By Age, Men and Women, N, 2013 .............................................. 44
Figure 6: 10MM, Incident Cases of MS, By Sex, N, 2013 .......................................................................... 46
Figure 7: 10MM, MS Subtype Distributions, %*, 2013–2023 ................................................................. 47
Introduction

2 Introduction

2.1 Catalyst

Multiple sclerosis (MS) affects 2.5 million people worldwide each year and is the most debilitating neurological disease in young adults (Fernandes de Abreu et al., 2009).

- GlobalData epidemiologists expect that the number of prevalent and incident cases of MS will increase during the forecast period (2013–2023) in the 10 major markets (10MM) (the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India).

- In 2013, GlobalData epidemiologists forecast that there were a total of 904,908 prevalent cases of MS in the 10MM, and by 2023 GlobalData epidemiologists forecast that the number of prevalent cases will grow to 940,413 prevalent cases.

- This report provides an overview of the risk factors and comorbidities, and global and historical trends of MS in the 10MM. It includes a 10-year epidemiological forecast of MS prevalent and incident cases segmented by sex and age (in five-year increments beginning at 20 years and ending at ≥85 years) in these markets.

- To provide a thorough description of the MS patient population in each country, GlobalData epidemiologists segmented MS cases by age and sex. Moreover, cases are segmented into three common sub-types: relapsing-remitting MS, primary progressive MS, and secondary progressive MS.

- A major strength of this analysis is that the forecast methodology was consistent across the 10MM to allow for a meaningful comparison of the patient populations in each country.

2.3 Upcoming Reports

4.3 About GlobalData

GlobalData is a leading global provider of business intelligence in the Healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports and forecasts. Our analysis is supported by a 24/7 client support and analyst team.

GlobalData has offices in New York, San Francisco, Boston, London, India, Korea, Japan, Singapore, and Australia.

4.4 About EpiCast

EpiCast is a series of premier epidemiology reports written and developed by Master's- and PhD-level epidemiologists.

EpiCast Reports are in-depth, high quality, transparent, and market-driven, providing expert analysis of epidemiological trends and forecasting of patient populations for major markets. Specifically, the reports identify disease trends over a 10-year forecast period in six to eight major markets (US, France, Germany, Italy, Spain, UK, and Japan). Additional countries, such as Canada, Brazil, China, and India, are covered in these reports if their markets are highly relevant.
4.5 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher, GlobalData.